Recently, biological agents targeting the proprotein convertase subtilisin-kexin type 9 (PCSK9) have been shown to reduce LDL-C by 50–60% [134] and alleviate NAFLD [135]. Here, PCSK9 is linked to metabolic dysfunction-associated steatotic liver disease.